anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
BioAtla · pitchdeck

BioAtla | IPO Presentation Deck | 31 slides

31 pages · 5 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

BioAtla | IPO Presentation Deck | 31 slides

BioAtla · 2020-12
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 17 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits
— 0/1 slides
100% 1/1 slides · 2 hits 100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Solution 2 slides 100% 2/2 slides 100% 2/2 slides · 14 hits
— 0/2 slides
— 0/2 slides
50% 1/2 slides 100% 2/2 slides
— 0/2 slides
Market Size 2 slides 100% 2/2 slides 100% 2/2 slides · 12 hits
— 0/2 slides
— 0/2 slides
50% 1/2 slides 100% 2/2 slides 50% 1/2 slides Traction 10 slides 100% 10/10 slides 100% 10/10 slides · 53 hits
— 0/10 slides
70% 7/10 slides 40% 4/10 slides 100% 10/10 slides 40% 4/10 slides Team 2 slides 100% 2/2 slides 100% 2/2 slides · 10 hits
— 0/2 slides
— 0/2 slides
— 0/2 slides
100% 2/2 slides
— 0/2 slides

Slide inventory

31
every slide · same image gating as the playbook
01
Slide 1
The slide features a scientific illustration of antibody-cell interaction.front_matter
Open slide detail
02
other
Open slide detail
03
The slide provides specific financial and operational details regarding the company's public offering.other
Open slide detail
04
Slide provides a snapshot of company metrics and key institutional investors.summarize
Open slide detail
05
The slide uses a grid layout to present 8 key team members with their headshots, titles, and logos of past companies.other
Open slide detailBeat · Team
06
The slide uses a four-column layout to summarize key business drivers.summarize
Open slide detailBeat · Team
07
The slide uses a Gantt-style visualization to show the progress of various drug candidates through clinical phases.plan_implementation
Open slide detail
08
Includes a biological diagram of pH levels in human organs and a pHLIP intensity heatmap.present_solution
Open slide detailBeat · Solution
09
Includes three distinct data visualizations: a pH-dependent binding curve, a pharmacokinetic exposure curve, and a toxicity (ALT) bar chart.present_solution
Open slide detailBeat · Solution
10
The slide uses a three-part process flow to establish clinical validation followed by a data table for market sizing.size_opportunity
Open slide detailBeat · Market Size
11
The slide uses a logical flow from unmet need to regulatory advantage to commercial validation.size_opportunity
Open slide detailBeat · Market SizeLoop · Why Now
12
Includes specific clinical trial metrics and radiological evidence of efficacy.show_traction
Open slide detailBeat · TractionLoop · Why Now
13
The slide uses a waterfall chart to demonstrate efficacy in a specific biomarker-positive patient.show_traction
Open slide detailBeat · TractionLoop · Why Now
14
Includes clinical trial safety data and comparative toxicity analysis.compare_peers
Open slide detailBeat · TractionLoop · Why Now
15
Includes specific trial design details for Sarcoma and NSCLC, including interim analysis points and data read-outs.plan_implementation
Open slide detailBeat · TractionLoop · Why Now
16
The slide uses a numbered list for the strategic rationale and a table for the market sizing data.size_opportunity
Open slide detailBeat · Traction
17
Waterfall chart displays maximum percentage change from baseline in sum of target lesions across different patient cohorts.show_traction
Open slide detailBeat · Traction
18
The slide uses a before-after comparison of clinical imaging to demonstrate drug efficacy.show_traction
Open slide detailBeat · Traction
19
The table displays safety population data for N=3 and N=7 patients.analyze_data
Open slide detailBeat · Traction
20
Includes a synthetic arm for interim analysis and specifies patient criteria for NSCLC and melanoma.plan_implementation
Open slide detailBeat · Traction
21
The slide uses a split-column layout to compare two drug candidates (BA3011 and BA3021) and a right-hand column for safety.show_traction
Open slide detailBeat · Traction
22
The slide uses a comparison table to contrast monotherapy with combination therapy, highlighting the trade-off between improved survival and increased adverse eframe_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
23
The slide compares efficacy (tumor volume) and safety (GI symptoms) of BA3071 against standard I/O therapies.show_traction
Open slide detailLoop · Cost Of Inaction
24
The slide outlines a licensing deal structure and clinical progress.show_traction
Open slide detailLoop · Cost Of Inaction
25
The slide illustrates a bispecific antibody binding to a tumor cell and a T cell, with four key value propositions listed below.present_solution
Open slide detailLoop · Cost Of Inaction
26
The slide uses a comparative framework to highlight the therapeutic index advantage of the CAB technology.show_traction
Open slide detailLoop · Cost Of Inaction
27
Uses red stars to denote specific data readouts or regulatory filings.plan_implementation
Open slide detailLoop · Cost Of Inaction
28
The slide emphasizes a 'patent minefield' strategy to protect products.other
Open slide detailLoop · Cost Of Inaction
29
Slide highlights financial backing to establish credibility.show_traction
Open slide detailLoop · Cost Of Inaction
30
summarize
Open slide detailLoop · Cost Of Inaction
31
front_matter
Open slide detail